New therapies for Multiple Sclerosis

Interviewed by Steven E. Greer, MD

Barbara Giesser, MD, neurologist and Medical Director of the Multiple Sclerosis Center at UCLA, discusses the soon-to-be-approved new therapy for MS called BG-12 (fumarate), made by Biogen Idec. Biogen also makes Tysabri, which is known to cause the very serious adverse event of PML caused by the JC virus.

Dr. Giesser discusses whether BG-12 will be rapidly adopted as a new first-line therapy, and also replace existing options for failed first line therapy, such as Gilenya and Tysabri. She then reviews the recent NEJM publications on BG-12.


This entry was posted in Neurology, UCLA, Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *